Exemplar Abstract for Mycoplasma hyopneumoniae Maré and Switzer 1965 (Approved Lists 1980).

2003 ◽  
Author(s):  
Charles Thomas Parker ◽  
Dorothea Taylor ◽  
George M Garrity
Keyword(s):  
Mycoplasma Hyopneumoniae

Feldvalidierung einer real-time PCR zum Nachweis von Mycoplasma hyopneumoniae in Nasentupfermaterial von lebenden Schweinen

2005 ◽  
Vol 147 (9) ◽  
pp. 373-379 ◽  
Author(s):  
F. Zeeh ◽  
P. Kuhnert ◽  
R. Miserez ◽  
M. G. Doherr ◽  
W. Zimmermann
Keyword(s):  
Real Time ◽  
Real Time Pcr ◽  
Mycoplasma Hyopneumoniae

Immunoenhancement of Recombinant Neisseria meningitides PorB Protein on Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae Genetically Engineered Vaccines

2019 ◽  
Vol 26 (10) ◽  
pp. 776-784
Author(s):  
Rui Yang ◽  
Yu Tao ◽  
Gaojian Li ◽  
Jian Chen ◽  
Jianhong Shu ◽  
...  
Keyword(s):  
Recombinant Protein ◽  
Mycoplasma Hyopneumoniae ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus Type 2 ◽  
Genetically Engineered ◽  
Porcine Circovirus ◽  
Practical Applications ◽  
Neisseria Meningitides ◽  
Short Period

Background:Porcine circovirus and Mycoplasma hyopneumoniae can cause respiratory diseases in pigs, which cause serious economic loss in the worldwide pig industry. Currently, these infections are mainly prevented and controlled by vaccination. The new vaccines on the market are mainly composed of subunits and inactivated vaccines but usually have lower antigenicity than traditional live vaccines. Thus, there is an increasing need to develop new adjuvants that can cause rapid and long-lasting immunity to enhance the antigenic efficacy for vaccines. Studies have shown that meningococcal porin PorB can act as a ligand to combine with Toll-like receptors to activate the production of immunological projections and act as a vaccine immunological adjuvant.Objective:In this article, we expressed and purified the recombinant PorB protein and verified its immunogenicity against porcine circovirus type 2 and Mycoplasma hyopneumoniae genetically engineered vaccine.Methods:In this article, we used prokaryotic expression to express and purify recombinant PorB protein, four different concentrations of PorB protein, Freund's adjuvant with two genetically engineered vaccines were combined with subcutaneous immunization of mice.Results:Our study shows that the appropriate dose of the recombinant protein PorB can enhance the levels of humoral and cellular responses induced by two genetically engineered vaccines in a short period of time in mice. The PorB adjuvant group may cause statistically higher antibody titers for both genetically engineered vaccines compared to Freund's commercial adjuvant (P<0.001).Conclusion:The recombinant protein PorB may be a good candidate adjuvant for improving the protective effect of vaccines against porcine circovirus type 2 and Mycoplasma hyopneumoniae, and the protein can be used for future practical applications.

scholarly journals Perspectives for improvement of Mycoplasma hyopneumoniae vaccines in pigs

2021 ◽  
Vol 52 (1) ◽  
Author(s):  
Dominiek Maes ◽  
Filip Boyen ◽  
Bert Devriendt ◽  
Peter Kuhnert ◽  
Artur Summerfield ◽  
...  
Keyword(s):  
Immune Responses ◽  
Respiratory Infections ◽  
Mycoplasma Hyopneumoniae ◽  
Administration Route ◽  
Limited Effect ◽  
Partial Protection ◽  
Carrier Molecule ◽  
Humoral Responses ◽  
Porcine Respiratory ◽  
Selection Of

AbstractMycoplasma hyopneumoniae (M. hyopneumoniae) is one of the primary agents involved in the porcine respiratory disease complex, economically one of the most important diseases in pigs worldwide. The pathogen adheres to the ciliated epithelium of the trachea, bronchi, and bronchioles, causes damage to the mucosal clearance system, modulates the immune system and renders the animal more susceptible to other respiratory infections. The pathogenesis is very complex and not yet fully understood. Cell-mediated and likely also mucosal humoral responses are considered important for protection, although infected animals are not able to rapidly clear the pathogen from the respiratory tract. Vaccination is frequently practiced worldwide to control M. hyopneumoniae infections and the associated performance losses, animal welfare issues, and treatment costs. Commercial vaccines are mostly bacterins that are administered intramuscularly. However, the commercial vaccines provide only partial protection, they do not prevent infection and have a limited effect on transmission. Therefore, there is a need for novel vaccines that confer a better protection. The present paper gives a short overview of the pathogenesis and immune responses following M. hyopneumoniae infection, outlines the major limitations of the commercial vaccines and reviews the different experimental M. hyopneumoniae vaccines that have been developed and tested in mice and pigs. Most experimental subunit, DNA and vector vaccines are based on the P97 adhesin or other factors that are important for pathogen survival and pathogenesis. Other studies focused on bacterins combined with novel adjuvants. Very few efforts have been directed towards the development of attenuated vaccines, although such vaccines may have great potential. As cell-mediated and likely also humoral mucosal responses are important for protection, new vaccines should aim to target these arms of the immune response. The selection of proper antigens, administration route and type of adjuvant and carrier molecule is essential for success. Also practical aspects, such as cost of the vaccine, ease of production, transport and administration, and possible combination with vaccines against other porcine pathogens, are important. Possible avenues for further research to develop better vaccines and to achieve a more sustainable control of M. hyopneumoniae infections are discussed.

scholarly journals Genetic diversity of Mycoplasma hyopneumoniae isolates of abattoir pigs

2014 ◽  
Vol 168 (2-4) ◽  
pp. 348-356 ◽  
Author(s):  
Audrey Charlebois ◽  
Corinne Marois-Créhan ◽  
Pierre Hélie ◽  
Carl A. Gagnon ◽  
Marcelo Gottschalk ◽  
...  
Keyword(s):  
Genetic Diversity ◽  
Mycoplasma Hyopneumoniae

Assessment of a complement fixation test to detect Mycoplasma hyopneumoniae infection in pigs

1984 ◽  
Vol 61 (7) ◽  
pp. 216-218
Author(s):  
L. C. LLOYD ◽  
R. T. BADMAN ◽  
J. R. ETHERIDGE ◽  
K. McKECHNIE ◽  
H. IYER
Keyword(s):  
Complement Fixation Test ◽  
Complement Fixation ◽  
Mycoplasma Hyopneumoniae ◽  
Fixation Test
Sign in / Sign up

Export Citation Format

Share Document